MREO
Mereo BioPharma Group plc
NASDAQ · Healthcare · Biotechnology · GB
$0.25
−8.16%Aug 19, 2026, 00:00 UTC
Mereo BioPharma Group plc received a notice from NASDAQ on 2026-08-18 indicating non-compliance with the minimum bid price requirement under Rule 5550(a)(2), with a compliance deadline of 2027-02-16.
Aug 11, 2026, 00:00 UTC
Mereo BioPharma Group plc reported its Q2 2026 financial results, with zero revenue, a net loss of $7.005 million, and diluted EPS of -$0.01, while holding approximately $30 million in cash and cash equivalents as of June 30, 2026.
Jul 8, 2026, 00:00 UTC
Aura Biosciences appointed Jeremy Bender as a Class II director effective July 7, 2026.